Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Coherus BioSciences (NASDAQ: CHRS) has announced the upcoming presentation of interim data from its ongoing Phase 1 clinical trial of CHS-114, a selective, cytolytic anti-CCR8 antibody, at the 2025 AACR Annual Meeting. The study evaluates CHS-114 both as a monotherapy and in combination with toripalimab for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
The presentation, led by Dr. Francis Worden from the University of Michigan, will be featured as a poster (Abstract #CT038) in the Phase 0 and Phase 1 Clinical Trials section. The session is scheduled for Monday, April 28, 2025, from 9:00 a.m. to 12:00 p.m. CDT at McCormick Place Convention Center in Chicago.
Coherus BioSciences (NASDAQ: CHRS) ha annunciato la prossima presentazione dei dati intermedi del suo attuale studio clinico di Fase 1 su CHS-114, un anticorpo anti-CCR8 selettivo e citolitico, durante il Congresso Annuale AACR 2025. Lo studio valuta CHS-114 sia come monoterapia che in combinazione con toripalimab per pazienti con carcinoma squamoso della testa e del collo (HNSCC) recidivante/metastatico.
La presentazione, condotta dal Dr. Francis Worden dell'Università del Michigan, sarà presentata come poster (Abstract #CT038) nella sezione Studi Clinici di Fase 0 e Fase 1. La sessione è programmata per lunedì 28 aprile 2025, dalle 9:00 alle 12:00 CDT presso il McCormick Place Convention Center di Chicago.
Coherus BioSciences (NASDAQ: CHRS) ha anunciado la próxima presentación de datos interinos de su ensayo clínico en Fase 1 en curso sobre CHS-114, un anticuerpo anti-CCR8 selectivo y citolítico, en la Reunión Anual AACR 2025. El estudio evalúa CHS-114 tanto como monoterapia como en combinación con toripalimab para pacientes con carcinoma de células escamosas de cabeza y cuello (HNSCC) recurrente/metastásico.
La presentación, liderada por el Dr. Francis Worden de la Universidad de Michigan, se presentará como un póster (Resumen #CT038) en la sección de Ensayos Clínicos de Fase 0 y Fase 1. La sesión está programada para el lunes 28 de abril de 2025, de 9:00 a.m. a 12:00 p.m. CDT en el McCormick Place Convention Center de Chicago.
Coherus BioSciences (NASDAQ: CHRS)는 CHS-114에 대한 진행 중인 1상 임상 시험의 중간 데이터를 2025 AACR 연례 회의에서 발표할 예정이라고 발표했습니다. 이 연구는 재발성/전이성 두경부 편평세포암(HNSCC) 환자를 위해 CHS-114를 단독 요법 및 토리팔리맙과의 병용 요법으로 평가합니다.
미시간 대학교의 Francis Worden 박사가 이끄는 발표는 0상 및 1상 임상 시험 섹션에서 포스터(초록 #CT038)로 소개될 예정입니다. 이 세션은 2025년 4월 28일 월요일 오전 9시부터 오후 12시까지 CDT로 시카고의 McCormick Place Convention Center에서 진행됩니다.
Coherus BioSciences (NASDAQ: CHRS) a annoncé la prochaine présentation de données intermédiaires de son essai clinique de Phase 1 en cours sur CHS-114, un anticorps anti-CCR8 sélectif et cytolytique, lors de la réunion annuelle de l'AACR 2025. L'étude évalue CHS-114 à la fois comme monothérapie et en combinaison avec le toripalimab pour les patients atteints de carcinome épidermoïde récurrent/métastatique de la tête et du cou (HNSCC).
La présentation, dirigée par le Dr Francis Worden de l'Université du Michigan, sera présentée sous forme de poster (Résumé #CT038) dans la section des essais cliniques de Phase 0 et Phase 1. La session est prévue pour le lundi 28 avril 2025, de 9h00 à 12h00 CDT au McCormick Place Convention Center à Chicago.
Coherus BioSciences (NASDAQ: CHRS) hat die bevorstehende Präsentation von Zwischenberichten aus seiner laufenden Phase-1-Studie zu CHS-114, einem selektiven, zytolytischen Anti-CCR8-Antikörper, auf dem AACR-Jahrestreffen 2025 angekündigt. Die Studie bewertet CHS-114 sowohl als Monotherapie als auch in Kombination mit Toripalimab für Patienten mit rezidiviertem/metastasiertem Plattenepithelkarzinom des Kopfes und Halses (HNSCC).
Die Präsentation, geleitet von Dr. Francis Worden von der Universität Michigan, wird als Poster (Abstract #CT038) im Abschnitt der klinischen Studien der Phase 0 und Phase 1 vorgestellt. Die Sitzung ist für Montag, den 28. April 2025, von 9:00 bis 12:00 Uhr CDT im McCormick Place Convention Center in Chicago geplant.
- Phase 1 trial data selected for presentation at major cancer research conference (AACR)
- None.
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster presentation at the upcoming 2025 AACR Annual Meeting, being held April 25-30, 2025, at McCormick Place Convention Center in Chicago, Illinois.
AACR 2025 Presentation Details
Title: Phase 1 study of anti-CCR8 antibody CHS-114 with and without anti-PD-1 antibody toripalimab in patients with advanced solid tumors
Lead Author: Francis Worden, M.D., University of Michigan
Abstract #: CT038
Poster Session: Phase 0 and Phase 1 Clinical Trials
Poster Section 49: Poster board 17
Date and Time: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. CDT
About the CHS-114 Phase 1 Study
The Phase 1 study (NCT05635643) is a dose escalation, dose optimization and expansion study evaluating CHS-114 as a monotherapy and in combination with toripalimab, a next generation PD-1 inhibitor. Cohort 1a enrolled 20 patients with advanced solid tumors including 2 patients with HNSCC and evaluated multiple dose levels (5-1200 mg) of CHS-114 monotherapy. Cohort 1b evaluated two pharmacologically active doses of CHS-114 monotherapy in 12 HNSCC patients with paired tumor biopsies. Cohort 2 evaluated two pharmacologically active doses of CHS-114 with toripalimab in 7 patients. Primary objectives are to optimize the CHS-114 dose(s) for expansion and evaluate the safety of CHS-114 with toripalimab. Secondary objectives were to evaluate the safety, PK and antitumor activity of CHS-114 with and without toripalimab and assess biomarkers including changes in regulatory T cells (Tregs) and CD8+ T cells in paired tumor biopsies and other immune biomarkers.
About CHS-114
CHS-114, an afucosylated, cytolytic CCR8 monoclonal antibody, is designed to selectively target human CCR8 and preferentially kill CCR8+ Tregs within the tumor microenvironment while preserving CD8+ effector T cells and Tregs in normal tissue. In preclinical studies, CHS-114 induced antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) to deplete tumoral CCR8+ Tregs. In addition, treatment with CHS-114 alone reduced tumor growth in murine models, and enhanced antitumor activity was observed in combination with anti-PD-1 treatment. CHS-114 is currently being evaluated in two Phase 1 clinical trials as monotherapy with and without toripalimab in advanced solid tumors, including head and neck cancer (NCT05635643) and gastric cancer (NCT06657144).
About Coherus BioSciences
Coherus is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), with growing revenues and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for toripalimab in combination with both our pipeline candidates as well as our partners’, driving multiple development and sales synergies from proprietary combinations.
Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in three ongoing clinical studies: a Phase 1/2 study in advanced solid tumors including combination with toripalimab in NSCLC, a Phase 2 study in HCC, and randomized Phase 2 study in HCC evaluating casdozokitug in combination with toripalimab and bevacizumab. CHS-114 is a highly selective, competitively positioned, cytolytic anti-CCR8 antibody currently in a Phase 1 study in patients with advanced solid tumors, including HNSCC and gastric cancer.
Coherus markets LOQTORZI, a novel next-generation PD-1 inhibitor, and UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta. In December 2024, Coherus announced the planned divestiture of its UDENYCA franchise. The transaction is expected to close late in the first quarter or early in the second quarter of 2025.
Neulasta® is a registered trademark of Amgen, Inc.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus’ expectations about identifying synergies between its I-O pipeline and its commercial operations; Coherus’ projections that its I-O pipeline will be able to enhance outcomes for cancer patients; and Coherus’ statements about its expectations about consummating the proposed transaction for the divestiture of the UDENYCA franchise at all or in the estimated time frame.
Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to Coherus’ existing and potential collaboration partners; risks of Coherus’ reliance on third-parties; the risks and uncertainties related to manufacturing and supply of Coherus’ products, the risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of Coherus’ regulatory filings; uncertainties as to the timing for completion of the proposed transaction; uncertainties as to the Company’s ability to satisfy all conditions required to consummate the proposed transaction for the divestiture of UDENYCA; the possibility that competing offers will be made by third parties; the occurrence of any event, change or other circumstance that may give rise to a right of one or both parties to terminate the agreement to divest UDENYCA; the possibility that the proposed transaction for the divestiture of UDENYCA may not be completed in the time frame expected by the Company or at all. All forward-looking statements contained in this press release speak only as of the date of this press release. Unless required by law, the Company is not under any duty and undertakes no obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 17, 2025, including the section therein captioned “Risk Factors” and in other documents Coherus files with the SEC including the proxy statement of the Company relating to the proposed transaction for the divestiture of UDENYCA filed with the SEC on January 28, 2025.
UDENYCA® and LOQTORZI®, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners unless otherwise noted. Trademarks and trade names of other companies appearing in this press release are, to the knowledge of Coherus, the property of their respective owners.
Coherus Contact Information:
For Investors:
Jodi Sievers
VP, Investor Relations & Corporate Communications
IR@coherus.com
For Media:
Argot Partners
(212) 600-1902
coherus@argotpartners.com
FAQ
What is the purpose of Coherus BioSciences' Phase 1 trial for CHS-114 (CHRS)?
When will Coherus (CHRS) present the CHS-114 trial data at AACR 2025?
What type of cancer is being targeted in the CHRS CHS-114 Phase 1 trial?
Who is the lead investigator for the Coherus (CHRS) CHS-114 Phase 1 trial?
